(AGENPARL) - Roma, 10 Ottobre 2025 - (AGENPARL) – Fri 10 October 2025 Results presented today at ESGCT 2025
PARIS, France, LUND, Sweden (October 10, 2025) – Genethon, a worldwide pioneer
and leader in research and development of gene therapy for rare genetic
diseases, and Hansa Biopharma, a Sweden-based leader in IgG cleaving enzyme
technology announced today that a patient with a rare liver disease and immunity
to the AAV vector has been successfully treated with Genethon’s AAV-based
GNT0003 gene therapy for Crigler-Najjar syndrome, following prior administration
of imlifidase, an enzyme capable of temporarily inhibiting the immune response.
This encouraging result, achieved in a clinical trial, is a significant advance
in the treatment of patients with immunity to AAVs who were previously
ineligible for clinical trials and existing gene therapy treatments.
Gene therapy involves injecting a gene drug into an organism using a vector, a
“means of transport” usually derived from viruses, such as AAVs (adeno
-associated viruses), which are commonly used for gene therapy in for example
neuromuscular, liver, and eye diseases. Initial contact with the natural virus
can cause the body to develop immunoglobulin G (IgG) antibodies that neutralize
AAVs. It is estimated that one in three people is naturally immune to AAVs,
thereby excluding a large number of patients from the possibility of benefiting
from gene therapy using an AAV vector. To evaluate potential options for
treating patients with natural immunity to AAVs, researchers at Genethon tested
imlifidase, an enzyme developed by Hansa Biopharma, as a pre-treatment. This
enzyme is capable of cleaving IgG, thereby rapidly and significantly reducing
the level of anti-AAV antibodies and allowing the administration of a gene
therapy drug candidate.
Dr. Jérémy Do Cao (Béclère Hospital, AP-HP, France) presented at the 2025
congress of the European Society of Gene & Cell Therapy (ESGCT), the results of
using imlifidase as a pre-treatment for GNT0003 gene therapy in a patient with a
severe form of Crigler–Najjar syndrome who is naturally immune to the AAV8
vector, as part of the clinical trial (GNT-018-IDES) conducted by Genethon in
collaboration with Hansa Biopharma.
In this first patient treated, the study demonstrated:
· the feasibility and safety of this approach: imlifidase administered prior
to GNT0003 gene therapy successfully cleaved and inactivated the patient’s
antibodies and enabled treatment with GNT0003. No severe side effects related to
GNT0003 or imlifidase were reported.
· initial efficacy data: GNT0003, Genethon’s gene therapy drug candidate
significantly lowered the patient’s bilirubin levels, enabling her to stop hours
of daily phototherapy, which had been essential to her survival until then. The
phototherapy has been interrupted sixteen weeks after the injection, as planned
in the protocol. Additional data will be needed to confirm this efficacy in the
longer term.
This is the first time that gene therapy has been successfully administered to a
patient with Crigler–Najjar syndrome who has antibodies against AAV8. If the
results are confirmed in the next stages of the trial, this approach could
become a promising option for patients with antibodies to AAVs, who are
currently ineligible for clinical trials and existing gene therapy treatments.
“It’s incredible to have had the chance to witness the clinical translation of
this project, which I saw come to life in our laboratory,” said Giuseppe
Ronzitti, Head of the Immunology and Liver Disease Laboratory and Director of
Scientific Forecasting at Genethon. “It’s a project that involved a significant
portion of Genethon working toward a common goal. The preliminary data we’ve
obtained indicate that we still have a lot to learn about the immune response to
AAV vectors, but the solution is potentially there.”
— ENDS —
Contacts for more information:
Evan Ballantyne, Chief Financial Officer
Kerstin Falck, VP Global Corporate Affairs
Notes to editors
About imlifidase
Imlifidase is a unique antibody-cleaving enzyme, originating from Streptococcus
pyogenes, that specifically targets IgG and inhibits the IgG-mediated immune
response. [(6)] It has a rapid onset of action, cleaving IgG antibodies and
inhibiting their activity within hours of administration. Imlifidase has
conditional marketing approval in EU, Norway, Iceland, Lichtenstein and the UK
and is marketed under the trade name IDEFIRIX® for the desensitization treatment
of highly sensitized adult kidney transplant patients with a positive crossmatch
against an available deceased donor. [(6)] Is also approved in Switzerland and
Australia.
About GNT003
The drug candidate GNT-0003, developed by Genethon to treat Crigler-Najjar
syndrome, is currently being evaluated in a trial (GNT-012-CRIG) conducted in
France, the Netherlands, and Italy in patients with no pre-existing immunity to
AAV, with encouraging results (https://www.genethon.fr/genethon-et-hansa
-biopharma-annoncent-le-debut-de-lessai-clinique-de-phase-2-de-limlifidase-en
-pre-traitement-a-la-therapie-genique-gnt-0003-chez-les-patients-atteints-du
-syndrome-de-crigler-najja/).[.(5)]
About Crigler-Najjar syndrome
Crigler-Najjar syndrome is a rare genetic liver disease characterized by
abnormally high levels of bilirubin in the blood (hyperbilirubinemia), which
leads to irreversible neurological damage manifested as muscle weakness,
lethargy, deafness, mental retardation, and eye movement paralysis. This
accumulation of bilirubin is caused by a deficiency of the UGT1A1enzyme,
responsible for transforming bilirubin into a substance that can be eliminated
by the body. It can result in significant neurological damage and death if not
treated quickly. At present, patients must undergo prolonged daily phototherapy
(often more than 10 hours a day, sometimes up to 15 hours a day) to keep their
bilirubin levels below the toxicity threshold. Crigler-Najjar syndrome is an
ultra-rare disease affecting less than one in one million people per year. Liver
transplantation remains the only definitive cure to date, but is associated with
significant morbidity and mortality, as well as graft shortage. [(7)]
About Hansa Biopharma
Hansa Biopharma AB is a pioneering commercial-stage biopharmaceutical company on
a mission to develop and commercialize innovative, lifesaving and life-altering
treatments for patients with rare immunological conditions. The company has a
rich and expanding research and development program based on proprietary IgG
-cleaving enzyme technology platform, to address serious unmet medical needs in
autoimmune diseases, gene therapy and transplantation. The company’s portfolio
includes imlifidase, a first-in-class immunoglobulin G (IgG) antibody-cleaving
enzyme therapy, which has been shown to enable kidney transplantation in highly
sensitized patients and HNSA-5487, a next-generation IgG cleaving molecule with
redosing potential. Hansa Biopharma is based in Lund, Sweden, and has operations
in Europe and the United States. The company is listed on Nasdaq Stockholm under
the ticker HNSA. Find out more at https://www.hansabiopharma.com/ and on
LinkedIn (https://www.linkedin.com/company/hansa-medical-ab/).
About Genethon
A pioneer in the discovery and development of gene therapies for rare diseases,
Genethon is a nonprofit laboratory created by the AFM-Telethon. A first gene
therapy drug, to which Genethon contributed, has been approved for marketing for
spinal muscular atrophy. With more than 240 scientists and experts, Genethon’s
goal is to develop innovative therapies that change the lives of patients
suffering from rare genetic diseases. Thirteen gene therapy products developed
by Genethon or to which Genethon has contributed are currently undergoing
clinical trials for diseases of the liver, blood, immune system, muscles, and
eyes. Seven other products are in preparation for clinical trials over the next
five years. Find out more on visit http://www.genethon.com
References
1. Boutin S, et al. Prevalence of serum IgG and neutralizing factors against
adeno-associated virus (AAV) types 1, 2, 5, 6, 8, and 9 in the healthy
population: implications for gene therapy using AAV vectors. Hum Gene Ther. 2010
2. Calcedo R, Wilson JM. Humoral Immune Response to AAV. Front Immunol. 2013
3. Veron P, Leborgne C, Monteilhet V, Boutin S, Martin S, Moullier P, Masurier
C. Humoral and cellular capsid-specific immune responses to adeno-associated
virus type 1 in randomized healthy donors. J Immunol. 2012 Jun 15;188(12):6418
4. Kruzik A, et al. Prevalence of Anti-Adeno-Associated Virus Immune Responses
in International Cohorts of Healthy Donors. Mol Ther Methods Clin Dev. 2019 Jun
6. European Medicines Agency. Idefirix[®] summary of product characteristics.
Available at: https://www.ema.europa.eu/en/documents/product
-information/idefirix-epar-product-information_en.pdf.
7. https://www.genethon.com/our-pipeline/crigler-najjar-syndrome/
8. Lundstrom K. Viral Vectors in Gene Therapy: Where Do We Stand in 2023?
9. Boutin S, et al. Prevalence of serum IgG and neutralizing factors against
adeno-associated virus (AAV) types 1, 2, 5, 6, 8, and 9 in the healthy
population: implications for gene therapy using AAV vectors. Hum Gene Ther. 2010
10. Calcedo R, Wilson JM. Humoral Immune Response to AAV. Front Immunol. 2013
11. Veron P, Leborgne C, Monteilhet V, Boutin S, Martin S, Moullier P, Masurier
C. Humoral and cellular capsid-specific immune responses to adeno-associated
virus type 1 in randomized healthy donors. J Immunol. 2012 Jun 15;188(12):6418
12. Kruzik A, et al. Prevalence of Anti-Adeno-Associated Virus Immune Responses
in International Cohorts of Healthy Donors. Mol Ther Methods Clin Dev. 2019 Jun
13. Falese L, et al. Strategy to detect pre-existing immunity to AAV gene
therapy. Gene Ther. 2017 Dec;24(12):768-778. doi: 10.1038/gt.2017.95. Epub 2017
14. Leborgne C, et al. IgG-cleaving endopeptidase enables in vivo gene therapy
in the presence of anti-AAV neutralizing antibodies. Nat Med. 2020
Jul;26(7):1096-1101. doi: 10.1038/s41591-020-0911-7. Epub 2020 Jun 1. PMID:
15. Au H.K, et al. (2022) Gene Therapy Advances: A Meta-Analysis of AAV Usage in
Clinical Settings. Front. Med. 8:809118. doi: 10.3389/fmed.2021.809118
If you would rather not receive future communications from Hansa Biopharma AB, please go to https://optout.ne.cision.com/en/NAnyyk7URtExeYqb62zMtBLVmBp9t83P6EAzqC7gDTXz4wiJy6YG17JszZXwXLxoTKLqYdTAkcPwH4Tw2dSVaDKyYCWSj1VxPrVCjQd2Dt2SQ.
Hansa Biopharma AB, Scheelevägen 22, Lund, 22362 Sweden
————————————————————
This information was brought to you by Cision http://news.cision.com
The following files are available for download:
If you would rather not receive future communications from Hansa Biopharma AB, please go to https://optout.ne.cision.com/en/NAnyyk7URtExeYqb62zMtBLVmBp9t83P6EAzqC7gDTXz4wiJy6YG17JszZXwXLxoTKLqYdTAkcPwH4Tw2dSVaDKyYCWSj1VxPrVCjQd2Dt2SQ.
Hansa Biopharma AB, Scheelevägen 22, Lund, 22362 Sweden
Report this content
Trending
- Milano. De Corato (FdI): Perde primo posto per qualità vita, causa è sicurezza
- Nota stampa ACAP – resoconto Campionati Italiani di AVICOLTURA ad Arezzo
- Federazioni sportive, sicurezza sul lavoro: l’ASL Roma 3 comunica ad Agenparl che dal 2021 non risultano controlli nelle sedi federali
- MANOVRA, IL SAP INCONTRA ESPONENTI COALIZIONE CENTROSINISTRA: CORICA, IL FINANZIAMENTO DELLA PREVIDENZA DEDICATA DEVE ESSERE PRIORITARIO
- ITALIA-UK, CATTANEO (FI): “CONGRATULAZIONI A PALMA D’AMBROSIO, NUOVA CONSOLE GENERALE D’ITALIA A LONDRA”
- GIURAMENTO DEL NUOVO GIUDICE COSTITUZIONALE ALBERTO GIUSTI
- AGRICOLTURA, CERRETO (FDI): CONTROLLI SU DOP E IGP, TUTELIAMO IMPRESE ONESTE E MOZZARELLA DI BUFALA CAMPANA
- Pino Rauti nel centenario della nascita – L’uomo, il politico, l’intellettuale e le idee – Martedì alle 11.30 inaugurazione mostra – Diretta webtv – Intervengono Rampelli e Trancassini
- Mercoledì 18 novembre 2026 alle ore 9.00 seduta congiunta di Prima e Quinta Commissione Consiliare
- AGENDA CAMERA DI DOMANI, MARTEDÌ 17 NOVEMBRE